Overview

The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the effect of ginkgo biloba (steady state) on the pharmacokinetics of a single dose of the UGT-substrate raltegravir. Furthermore the safety profile of the combination is studied.
Phase:
Phase 1
Details
Lead Sponsor:
Radboud University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Raltegravir Potassium